Compounds > methylestrenolone
Page last updated: 2024-12-10

methylestrenolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methylestrenolone: was MH 1963-92; METHYLESTRENOLONE & METHYLNORTESTOSTERONE were see NORMETHANDROLONE 1963-92; use ESTRENES to search NORMETHANDROLONE 1966-92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284597
CHEMBL ID2106801
CHEBI ID34896
SCHEMBL ID148631
MeSH IDM0198315

Synonyms (65)

Synonym
17alpha-methyl-17beta-hydroxyestr-4-en-3-one
unii-743f1z557a
743f1z557a ,
(17beta)-17-hydroxy-17-methylestr-4-en-3-one
estr-4-en-3-one, 17-hydroxy-17-methyl-, (17beta)-
17-beta-hydroxy-17-alpha-methyloestr-4-en-3-one
ai3-52808
estr-4-en-3-one, 17-beta-hydroxy-17-alpha-methyl-
19-nor-17-alpha-methyltestosterone
17alpha-methyl-17beta-hydroxy-19-nor-4-androsten-3-one
17alpha-methylestrenolone
orga-steron
estr-4-en-3-one, 17beta-hydroxy-17-methyl-
einecs 208-183-0
17-alpha-methyl-17-beta-hydroxy-4-estren-3-one
brn 2622263
nsc 10039
methylnortestosterone
orosteron
17-beta-hydroxy-17-methylestr-4-en-3-one
methyloestrenolone
17beta-hydroxy-17-methyl-4-estren-3-on
nsc-10039
17.alpha.-methyl-19-nortestosterone
17-methyl-19-nortestosterone
17.alpha.-methyl-17.beta.-hydroxy-19-nor-4-androsten-3-one
matronal
514-61-4
estr-4-en-3-one, 17.beta.-hydroxy-17-methyl-
normethandrone
metalutin
methalutin
lutenin
19-nortestosterone, 17-methyl-
orgasteron
methylestrenolone
normethanedrolone
normethandrolone
17.alpha.-methylestrenolone
17alpha-methyl-19-nortestosterone
(8r,9s,10r,13s,14s,17s)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
normethisterone
A828605
(8r,9s,10r,13s,14s,17s)-13,17-dimethyl-17-oxidanyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
normetandrone
chebi:34896 ,
CHEMBL2106801
normethandrone [mart.]
normethandrone [mi]
normethandrone [who-dd]
17.alpha.-methyl-17.beta.-hydroxyestr-4-en-3-one
SCHEMBL148631
W-105887
19-nor-17-.alpha.-methyltestosterone
17-.alpha.-methyl-17-.beta.-hydroxy-4-estren-3-one
ZXSWTMLNIIZPET-ZOFHRBRSSA-N
17.alpha.-hydroxy-17.beta.-methylestr-4-en-3-one #
17-.beta.-hydroxy-17-methylestr-4-en-3-one
estr-4-en-3-one, 17-.beta.-hydroxy-17-.alpha.-methyl-
estr-4-en-3-one, 17-hydroxy-17-methyl-, (17.beta.)-
17.alpha.-methyl-19-norandrost-4-en-17.beta.-ol-3-one
DTXSID4023383
17beta-hydroxy-17alpha-methylestr-4-en-3-one
DB13533
Q6824007

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The contribution of lymphatic transport to the oral bioavailability of methylnortestosterone (M) after oral administration of the lipophilic prodrug methylnortestosterone undecanoate (MU) has been evaluated, and the sensitivity of lymphatic MU transport to lymphatic lipid transport has been investigated."( Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
Charman, WN; Edwards, GA; Faassen, WA; Nguyen, G; Porter, CJ; White, KL, 2009)		0.35

Dosage Studied

ExcerptRelevanceReference
" M and MU were administered intravenously and orally to greyhound dogs to determine absolute bioavailability after oral dosing of MU."( Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
Charman, WN; Edwards, GA; Faassen, WA; Nguyen, G; Porter, CJ; White, KL, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
estrogenA hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID87088The compound was tested for the seminal vesicle weight after -0.75 ug topical application for 14 days.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID87091The compound was tested for the treated flank organ weight after -0.375 ug topical application for 14 days.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID87087The compound was tested for the seminal vesicle weight after -0.375 ug topical application for 14 days.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID87094The compound was tested for the treated flank organ weight after -5 mg sc administration for 14 days1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID87093The compound was tested for the treated flank organ weight after -1 mg sc administration for 14 days. 1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID87092The compound was tested for the treated flank organ weight after -0.75 ug topical application for 14 days.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID87090The compound was tested for the seminal vesicle weight after -5 mg sc administration for 14 days.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID162617Relative binding affinity against progestin receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID74389Relative binding affinity against glucocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID87089The compound was tested for the seminal vesicle weight after -1 mg sc administration for 14 days.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.
AID162435Relative binding affinity for progesterone receptor(PgR) in human T47D cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID126441Relative binding affinity for the mineralocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID212922Relative binding affinity to the testosterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID39318Relative binding affinity for androgen receptor (AR) in rat uterus1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID39152Relative binding affinity for androgen receptor (AR) in human MCF-7 cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID69853Relative binding affinity against Estrogen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID39454Relative binding affinity against androgen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID162462Relative binding affinity to the progesterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (72.41)18.7374
1990's5 (8.62)18.2507
2000's7 (12.07)29.6817
2010's2 (3.45)24.3611
2020's2 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.63 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.94%)5.53%
Reviews1 (1.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (95.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
flutamide
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.		1.9810(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
sulfobromophthalein
Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.		1.94102-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		2.342016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
lynestrenol
Lynestrenol: A synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).		7.8540steroid
norethandrolone
Norethandrolone: A synthetic hormone with anabolic and androgenic properties and moderate progestational activity.		2.8540corticosteroid hormone
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		2.342017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.		1.941017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		2.633017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		3.26017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
norethynodrel
Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL.		1.9310oxo steroid
fluoxymesterone
Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.		2.342011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
dydrogesterone
[no description available]		1.941020-oxo steroid;
3-oxo-Delta(4) steroid		progestin
chlormadinone acetate
Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).		1.9410corticosteroid hormone
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		5.6419017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
medroxyprogesterone
[no description available]		1.941017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		2.412017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
norgestrienone
Norgestrienone: A synthetic steroid with progestational and contraceptive activities.		2.3820steroidestrogen
gestrinone
Gestrinone: A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices.		2.3820oxo steroid
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		1.9410benzenes;
phenyl acetates
halofantrine
halofantrine: used in treatment of mild to moderate acute malaria		2.0510phenanthrenes
n-valyltryptophan
N-valyltryptophan: RN given refers to (L)-isomer		1.9810peptide
19-norprogesterone
19-norprogesterone: RN given refers to cpd without isomeric designation		2.3820corticosteroid hormone
mibolerone
mibolerone: prevents estrus in animals & prevents experimental lymphoid leukosis; minor descriptor (80-83); on-line & Index Medicus search NANDROLONE/AA (80-83); RN given refers to (7alpha,17beta)-isomer; structure. mibolerone : An androgen that is nalandrone carrying two methyl substituents at positions 7alpha and 17.		2.382017beta-hydroxy steroid;
3-oxo-Delta(4) steroid		anabolic agent;
androgen
metribolone
Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.		2.673017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
17-ketosteroids
17-Ketosteroids: Steroids that contain a ketone group at position 17.. 17-oxo steroid : Any oxo steroid carrying the oxo group at position 17.		2.3420
bilirubin
[no description available]		1.9410biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
pregnanediol
[no description available]		2.3420
isoleucyl-tyrosine
isoleucyl-tyrosine: a dipeptide with antihypertensive effect. Ile-Tyr : A dipeptide formed from L-isoleucine and L-tyrosine residues.		1.9810dipeptidemetabolite
trestolone
trestolone: structure given in first source; RN given refers to (7alpha,17beta)-isomer		1.9310
azaline
azaline: gonadorelin antagonist; RN & amino acid sequence given in first source		210
cetrorelix
cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.		2.0110oligopeptideantineoplastic agent;
GnRH antagonist
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		1.9410
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		01.9710
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9710
Acne
[description not available]		01.9610
Acne Vulgaris
A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.		01.9610
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		03.3420
Icterus
[description not available]		02.3420
Jaundice
A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.		07.3420
Abortion, Tubal
[description not available]		02.6230
Hypomenorrhea
[description not available]		02.3420
Abortion, Spontaneous
Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.		02.6230
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.5490
Abortion, Recurrent
[description not available]		01.9310
Abortion, Habitual
Three or more consecutive spontaneous abortions.		01.9310
Menstruation, Painful
[description not available]		01.9310
Dysmenorrhea
Painful menstruation.		06.9310
Abortion, Threatened
UTERINE BLEEDING from a GESTATION of less than 20 weeks without any CERVICAL DILATATION. It is characterized by vaginal bleeding, lower back discomfort, or midline pelvic cramping and a risk factor for MISCARRIAGE.		01.9310
Postpartum Amenorrhea
[description not available]		01.9310
Amenorrhea
Absence of menstruation.		06.9310
Emaciation
Clinical manifestation of excessive LEANNESS usually caused by disease or a lack of nutrition (MALNUTRITION).		02.3420
Convalescence
The period of recovery following an illness.		01.9310
Adenohypophyseal Hyposecretion
[description not available]		01.9310
Hypopituitarism
Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions.		01.9310
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		01.9310
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		01.9310
Endometrioma
An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.		01.9310
Reproductive Sterility
[description not available]		01.9310
Sterility, Female
[description not available]		01.9310
Heavy Menstrual Bleeding
[description not available]		01.9310
Benign Neoplasms
[description not available]		01.9310
Endometriosis
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.		01.9310
Infertility
A reduced or absent capacity to reproduce.		01.9310
Infertility, Female
Diminished or absent ability of a female to achieve conception.		01.9310
Menorrhagia
Excessive uterine bleeding during MENSTRUATION.		01.9310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9310
Bonnevie-Ullrich Syndrome
This syndrome that was originally observed by Ullrich, and designated as identical to TURNER SYNDROME, related the webbing of the neck, loose skin and other anomalies of the syndrome to accumulation of fluid in the embryo starting at the head and dispersing to the extremities (as observed by Bonnevie in mice). Commonly observed at birth in Turner Syndrome and NOONAN SYNDROME; EDEMA of the extremities usually recedes by one year and is an early sign of Turner syndrome, especially in female neonates.		01.9410
Turner Syndrome
A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant.		01.9410
Embryopathies
[description not available]		01.9410
Ambiguous Genitalia
[description not available]		01.9410
Androgenization
[description not available]		01.9410
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		01.9410
Disorders of Sex Development
In gonochoristic organisms, congenital conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. Effects from exposure to abnormal levels of GONADAL HORMONES in the maternal environment, or disruption of the function of those hormones by ENDOCRINE DISRUPTORS are included.		01.9410
Cushing's Syndrome
[description not available]		01.9410
Cushing Syndrome
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.		01.9410
Atrophy, Muscle
[description not available]		02.0210
Muscular Atrophy
Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.		02.0210
Cancer of Prostate
[description not available]		02.0310
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0310